About NADH-ubiquinone oxidoreductase chain 1
NADH-ubiquinone oxidoreductase chain 1 (MT-ND1) is a protein
from Homo sapiens identified by UniProt accession
P03886, 318 residues long.
MolForge cross-references it against 0 known binders and
338 disease associations.
Target properties
| Protein name | NADH-ubiquinone oxidoreductase chain 1 |
|---|
| UniProt accession | P03886 |
|---|
| Gene | MT-ND1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 318 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (338)
Diseases linked to this target (Open Targets).
- Leber hereditary optic neuropathy · score 0.79
- MELAS syndrome · score 0.73
- MELAS · score 0.72
- mitochondrial disease · score 0.70
- mitochondrial complex I deficiency · score 0.67
- Mitochondrial non-syndromic sensorineural deafness · score 0.67
- type 2 diabetes mellitus · score 0.66
- sudden infant death syndrome · score 0.64
- diabetes mellitus · score 0.60
- polycystic ovary syndrome · score 0.60
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P03886-F1 | alphafold | PREDICTED | 91.73 | — |
Amino-acid sequence (318 residues)
MPMANLLLLI VPILIAMAFL MLTERKILGY MQLRKGPNVV GPYGLLQPFA DAMKLFTKEP LKPATSTITL YITAPTLALT IALLLWTPLP MPNPLVNLNL GLLFILATSS LAVYSILWSG WASNSNYALI GALRAVAQTI SYEVTLAIIL LSTLLMSGSF NLSTLITTQE HLWLLLPSWP LAMMWFISTL AETNRTPFDL AEGESELVSG FNIEYAAGPF ALFFMAEYTN IIMMNTLTTT IFLGTTYDAL SPELYTTYFV TKTLLLTSLF LWIRTAYPRF RYDQLMHLLW KNFLPLTLAL LMWYVSMPIT ISSIPPQT
Explore NADH-ubiquinone oxidoreductase chain 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets